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Abstract: 
The tetraspanin CD9 has been shown to interact with different members of the β1 and 
β3 subfamilies of integrins, regulating through these interactions cell adhesion, 
migration and signaling. Based on confocal microscopy co-localization and on co-
immunoprecipitation results, we report here that CD9 associates with the β2 integrin 
LFA-1 in different types of leukocytes including T, B and monocytic cells. This 
association is resistant to stringent solubilisation conditions which, together with data 
from chemical crosslinking, in situ Proximity Ligation Assays and pull-down 
experiments, suggests a primary/direct type of interaction mediated by the Large 
Extracellular Loop of the tetraspanin. CD9 exerts inhibitory effects on the adhesive 
function of LFA-1 and on LFA-1-dependent leukocyte cytotoxic activity. The 
mechanism responsible for this negative regulation exerted by CD9 on LFA-1 adhesion 
does not involve changes in the affinity state of this integrin but seems to be related to 
alterations in its state of aggregation.  
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1. Introduction 
The β2 subfamily of integrins comprises four distinct members, αLβ2, αMβ2, αXβ2, 
and αDβ2, that are selectively expressed on leukocytes (for review (Gahmberg et al., 
1999; Harris et al., 2000; Cabanas et al., 2008)). The integrin αLβ2, also termed LFA-1 
(Lymphocyte Function-associated Antigen-1) or CD11a/CD18 antigen, is expressed on 
most types of leukocytes and primarily on lymphocytes, whereas expression of the rest 
of members of this subfamily is rather restricted to myeloid cells. LFA-1 interacts with 
intercellular adhesion molecules (ICAM-1, -2, or -3), playing a pivotal role in many 
crucial leukocyte functions that require intercellular adhesion, such as extravasation into 
tissues, organization of the immune synapse and antigen presentation, inter-lymphocyte 
collaboration and killing of target cells by CTL or NK cells (Springer et al., 1987; Sims 
and Dustin, 2002; Hogg et al., 2003; Anikeeva et al., 2005). 
LFA-1 can exist in different states of activation regarding its ability to bind ligands. 
Resting T lymphocytes express LFA-1 with low affinity and avidity for ligands, 
necessary for their normal circulation in the blood as individual cells. However, 
activation by the TCR-CD3 complex or receptors for different cytokines and 
chemokines, results in rapid activation of LFA-1 enabling T cells to adhere to other 
cells (Dustin and Springer, 1989; van Kooyk et al., 1989; Cabanas et al., 2008). 
Activation of LFA-1 can be induced through changes in the affinity of individual 
integrin molecules, reflecting conformational alterations, or through changes in the 
valency of interactions with multivalent ligands (Carman and Springer, 2003). In terms 
of ligand binding affinity, at least three different conformational states of LFA-1 have 
been identified: a bent conformation of low affinity, an extended conformation with 
closed headpiece displaying intermediate affinity, and a high affinity extended 
conformation with open headpiece and separated intracellular tails (Carman and 
Springer, 2003; Hogg et al., 2011). PMA induces the intermediate affinity state but also 
increases the diffusion of LFA-1 molecules on the cell surface, which in the presence of 
multivalent ligand, leads to aggregation/clustering of this integrin (Carman and 
Springer, 2003; Kim et al., 2004). On the other hand, extracellular Mn2+ induces the 
high affinity conformation of LFA-1 (Dransfield et al., 1992b; Carman and Springer, 
2003) but also induces changes in the local density (i.e. the clustering) of integrin 
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molecules, which is reflected by changes in the number of effective adhesive bonds (i.e. 
the valency) with ligand (Rodriguez-Fernandez et al., 2001; Cluzel et al., 2005). 
CD9 is a member of the tetraspanin family of integral membrane proteins (Charrin et 
al., 2009; Yanez-Mo et al., 2009) abundantly expressed on the surface of endothelial 
cells, some leukocytes and many types of tumour cells (Sincock et al., 1997; Charrin et 
al., 2001; Hemler, 2013). CD9 was initially characterized as a lympho-hematopoietic 
marker (Boucheix et al., 1985) and received the name “Motility-Regulatory Protein” 
(MRP) (Miyake et al., 1991). CD9 has been also implicated in the formation and 
maintenance of muscular myotubes (Tachibana and Hemler, 1999), in nervous cell 
neurite outgrowth (Schmidt et al., 1996), and in sperm-oocyte fusion (Chen et al., 
1999). Like other tetraspanins, CD9 associates on the cell surface with different 
integrins and many of the functional effects that have been attributed to CD9 may be 
indeed related to its ability to associate to integrin molecules (Berditchevski, 2001; 
Bassani and Cingolani, 2012).  
Functional interactions of CD9 with several members of the β1 and β3 subfamilies of 
integrins have been reported, usually based on the effects exerted by CD9-specific 
mAbs on the associated integrin-dependent adhesion, migration and signalling 
(reviewed in (Berditchevski, 2001; Bassani and Cingolani, 2012). However, to our 
knowledge, only one published report includes some indication –merely based on co-
immunoprecipation evidence- suggestive of a possible interaction between CD9 and the 
β2 integrin subunit (Takeda et al., 2003), although this study did neither address the 
type or functional aspects of this interaction. In addition, functional association of LFA-
1 with tetraspanins CD81 (the most closely related to CD9) and CD82, has been 
described on T lymphocytes (Shibagaki et al., 1999; VanCompernolle et al., 2001), 
which prompted us to investigate in more detail whether CD9 is also functionally 
associated with the β2 integrin LFA-1 on leukocytes. 
We report here that CD9 associates directly with LFA-1 in different types of leukocytes 
and exerts inihibitory effects on its adhesive capacity and on leukocyte LFA-1-
dependent cytotoxic activity. 
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2. Materials and Methods 
Cells and cell cultures. Primary T lymphoblasts were obtained from peripheral blood 
mononuclear cells from healthy donors treated with 5 μg/ml phytohemaglutinin 
(Amersham Biosciences) for 48 h, as described previously (Dransfield et al., 1992a; 
Luque et al., 1996). Cells were then cultured for 7-10 days in RPMI-1640 containing 
10% FBS and 50 U/ml IL-2 (Eurocetus). HSB-2 and Jurkat (T cell lines), JY and Daudi 
(B cell lines) and THP-1 and U937 cells (monocytic cell lines) were cultured in RPMI-
1640 supplemented with 10% FBS, antibiotics and glutamine. THP-1 and U937 
differentiation into macrophage-like cells was induced with PMA (100 ng/ml) for 24 h. 
Expression Constructs and RNA silencing transfection. For stable transfection 
experiments, HSB-2 and U937 cells were electroporated with 20 μg pcDNA3-CD9 
plasmid at 200 V (2 x 10 ms pulses in a 0.4 cm electroporation cuvette) using an 
ECM830 BTX electroporation system and selected with 1 mg/ml G418. For CD9 
silencing, Jurkat cells were retroviraly transduced (OriGene Technologies) with the 
shRNA-coding plasmids TI356235 (the plasmid with the CD9 shRNA cassette insert) 
and TR20003 (“TR2” control plasmid without shRNA insert), according to 
manufacturer’s indications and selected with 1 μg/ml puromycin.  
Antibodies and reagents. ICAM-1-Fc chimeric protein consisting of the five domains of 
ICAM-1 fused to the Fc region of human IgG1 was prepared as described (Berendt et 
al., 1992). Anti-β-tubulin antiboby was purchased from Sigma and the anti-CD18 
biotin-conjugated antibody (MEM-48) from ImmunoTools. The antibodies anti-β2 
integrin Lia3/2 (Campanero et al., 1993) and TS1/18 (Sanchez-Madrid et al., 1983), 
anti-αL TP1/40 (Campanero et al., 1993) and TS1/11 (Sanchez-Madrid et al., 1983), 
anti-αM Bear-1 (Keizer et al., 1985) and anti-αX HC1/1 (Cabanas et al., 1988), anti-
CD9 VJ1/20 (Yanez-Mo et al., 1998), PAINS-10 and PAINS-13 (Gutierrez-Lopez et 
al., 2003), anti-CD147 VJ1/9 and anti-CD59 VJ1/12 (Yanez-Mo et al., 1998) and anti-
HSPA8 PAINS-18 (Gutierrez-Lopez et al., 2003; Gilsanz et al., 2013) were purified by 
protein A or protein-G affinity chromatography. The anti-CD81 5A6 mAb was kindly 
provided by Dr. Shoshana Levy (Stanford University School of Medicine, USA), the β2 
stimulatory mAb KIM185 by Dr. Martyn K. Robinson (UCB-Celltech., Slough, UK), 
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the anti-CD105 mAb P4A4 by Dr. Carmelo Bernabeu (CIB-CSIC, Madrid, Spain) and 
the anti-β2 mAb m24 by Dr. Nancy Hogg (Cancer Research UK, London, UK). 
Flow Cytometry Analysis. For protein surface expression analysis cells were washed 
twice in RPMI-1640, incubated with primary antibodies at 4 ºC for 30 min, followed by 
FITC-conjugated anti-mouse IgG (Sigma) and fixed in 2% formaldehyde in PBS. For 
flow cytometric analysis of m24 epitope expression, HSB-2 and JK cells were washed 
in cation-free PBS and incubated  for 15 min at 37 ºC with Mn2+ (10, 20, 40, 100 and 
400 μM) or with Ca2+/Mg2+ (0.5 mM and 1 mM respectively) in the presence of mAb 
24 (5 μg/ml), washed and stained with secondary FITC-anti-mouse IgG. Fluorescence 
was measured using a FACScanTM flow cytometer (Beckton-Dickinson). 
Immunofluorescence, Confocal and TIRF Microscopy. For immunofluorescence studies 
cells, treated or not with 0.4 mM Mn2+ for 20 min at 37 ºC, were seeded on 12-mm glass 
coverslips coated with poly-L-lysine (50 μg/ml). Cells were fixed in 2% 
paraformaldehyde, blocked in 1% BSA in TBS and incubated for 1 h with TS1/11 or 
TS1/18 mAbs (10 μg/ml), followed by secondary antibody Alexa FluorTM-594 anti-
mouse IgG (Invitrogen), rabbit polyclonal anti-CD9 antibody H-110 (Santa Cruz 
Biotechnology) and Alexa FluorTM-488 anti-rabbit IgG (Invitrogen). For THP-1 cells, 
Fc receptors were saturated with human gammaglobulin for 30 min, prior to fixation. 
Samples were mounted with Mowiol reagent (Calbiochem) and images were obtained 
with a Zeiss LSM510 Meta inverted microscope. Fluorescence co-localization 
histograms and Pearson coefficient values were obtained using the Fiji plug-in 
“Intensity correlation analysis” (Li et al., 2004; Schindelin et al., 2012). Fiji software 
was also used for setting the threshold and for detection and quantitation of fluorescent 
objects. 
For TIRF (total internal reflection fluorescence) miscroscopy, JK TR2 and JK shCD9 
cells were first activated with PMA (200 ng/ml for 2 hours), then plated onto ICAM-1-
Fc-coated (14 μg/ml) 35 mm petri dishes with glass bottom (2.5 x 105 cells/plate), and 
incubated for 90 min at 37 ºC to allow adhesion. After washing non adhered cells with 
PBS, adhered cells were fixed in 2% paraformaldehyde (10 min, room temperature) and 
then permeabilized with 0.3% Triton-X100 in TBS buffer. Immunoflourescence 
staining of beta-2 integrin with mAb TS1/18 was performed as described above, and 
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images were obtained with an inverted Olympus Xcellence IX83P2ZF TIRF 
miscroscopy system. Fiji software was used for setting the threshold and for detection 
and quantitation of fluorescence in clusters.  
Co-immunoprecipitations. Co-immunoprecipitation experiments were performed using 
intact cells, in order to detect only surface protein-protein interactions. Cells were 
incubated for 15 min at 37 ºC (or for 60 min at 4 ºC in parallel control experiments) 
with the specific TS1/18 (anti-β2) or VJ1/20 (anti-CD9) or control anti-CD105 and anti-
CD59  antibodies in the presence of 0.5 mM Ca2+/1 mM Mg2+, followed by washing the 
antibody excess. Cells were then lysed for 15 min at 4 ºC in TBS containing 1% Brij-97 
or 1% Triton-X100 in the presence of corresponding extracellular cations and protease 
inhibitors and, after removal of insoluble material, incubated overnight at 4 ºC with 
protein G-Sepharose. Beads were then washed with 1:5 diluted lysis buffer, boiled in 
nonreducing Laemmli buffer, resolved by 8% (for β2 detection) or 12% (for CD9) SDS-
PAGE and transferred onto nitrocellulose membranes. Membranes were then blocked 
with 3% BSA and developed with the β2 (MEM-48) or CD9 (VJ1/20) biotin-conjugated 
antibodies followed by streptavidin HRP (Thermo scientific) and ECL-
chemiluminiscence. 
Covalent chemical cross-linking. THP-1/PMA and JY cells were extracted in 1% Brij97 
lysis buffer (containing 20 mM Hepes,150 mM NaCl, 0.5 mM CaCl2, 3 mM MgCl2 and 
protease inhibitors), pH 7.4. After removal of insoluble material, lysates were treated 
with 0.25 mM thiol-cleavable cross-linker 3,3´-dithiobis(sulfosuccinimidylpropionate) 
(DTSSP) for 30 min at 4ºC. The cross-linking reaction was quenched for 15 min at 
room temperature with 10 mM glycine, pH 7.4, and then Triton X-100 was added to a 
final concentration of 1% (v/v) to cross-linked lysates and to parallel non-cross-linked 
lysates used as controls. Samples were immunoprecipitated with anti-β2 integrin mAb 
TS1/18, with anti-CD9 mAb VJ1/20 or with anti-CD9 pAb (H110), as indicated, 
resolved by SDS-PAGE either under reducing conditions (to break the thiol bond in 
DTSSP-crosslinked protein complexes) or under non-reducing conditions and 
subsequent immunoblotting with biotinylated anti-CD9 (VJ1/20) or anti-β2 integrin 
(MEM-48) mAbs, followed by streptavidin-HRP (Thermo Scientific) and ECL-
chemiluminiscence. 
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Pull-down assays. GST-fusion proteins containing the LEL region from human wt CD9, 
wt CD81 and wt CD63 were prepared as previously described (Higginbottom et al., 
2003; Barreiro et al., 2005; Gutierrez-Lopez et al., 2011). JY and THP-1 cells were 
washed three times in PBS and either left untreated or their surface proteins biotinylated 
with 1 mM EZ-LinkR Sulfo-NHS-LC-Biotin (Thermo Scientific) in PBS with 1mM 
CaCl2, 1mM MgCl2 for 30 minutes at 4ºC. Cells were then washed twice in PBS+100 
mM glycine to quench and remove excess biotin. Biotinylated and non-biotinylated 
cells were lysed in 1% Brij-97 or in 1% Triton-X100 buffer and incubated overnight at 
4 ºC with equal amounts of GST-fusion proteins, pulled down with glutathione-agarose 
3 h at 4 ºC, washed in 1:10 diluted lysis buffer and boiled in non-reducing Laemmli 
buffer. For non-biotinylated cells, the presence of β2 integrin in the pulled-down 
complexes was revealed by immunoblotting with biotinylated mAb MEM-48 and 
detection with streptavidin-HRP and ECL-chemiluminiscence. The levels of pulled-
down GST-fusion proteins were assessed by western-blot using an anti-GST rabbit 
polyclonal antibody (Santa Cruz Biotechnology). For surface-biotinylated cells, all 
lysate proteins pulled-down by GST or by LEL-GST-CD9 were isolated with 
glutathione-sepharose beads and detected with streptavidin-HRP and ECL-
chemiluminiscence.  
Cell Adhesion Assays. Static cell adhesion to ICAM-1-coated dishes was performed as 
described elsewhere (Rodriguez-Fernandez et al., 1999; Gilsanz et al., 2013). 96-well 
flat-bottom plates were pre-coated with 6 μg/ml (for THP-1/PMA and T-Lymphoblast 
cells) or 12 μg/ml (for JY, HSB2 and JK cells) of ICAM-1-Fc and blocked with 1% 
BSA. For PMA-stimulated cell adhesion, cells were incubated with 50 or 200 ng/ml of 
PMA in RMPI-1640 for 2 hours at 37 ºC. Cells were loaded with the fluorescent probe 
BCECF-AM (Sigma) and added (2 x 105 cells/well) in adhesion medium (Hepes 20 
mM, NaCl 149 mM, 2 mg/ml glucose), stimulated with 0.5 mM Ca2+/1 mM Mg2+ or 20-
400 μM Mn2+ and incubated for 20-60 min at 37 ºC. When indicated, 20 μg/ml of anti-
CD9 (VJ1/20, PAINS-10 and PAINS-13), anti-β2 (Lia3/2 and KIM185) or the control 
anti-HASP8 (PAINS-18) mAbs were pre-incubated with cells for 15 min at 4 ºC before 
transferring the plates to 37 ºC. The plates were then washed by gravity with warm PBS 
for 20 min at 37 ºC. The percentage of adherent cells was calculated by determining 
their fluorescence in a microplate reader (TecanGENios), considering as 100% the total 
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fluorescence of cells before washing. For determining cell adhesion under flow 
conditions, JK TR2 and JK shCD9 cells were first activated with PMA (100 ng/ml for 1 
h) and labeled with CFSE or CMAC fluorescent probes and allowed to adhere for 15 
min at 37°C to immobilized ICAM-1 (5 μg/ml). Shear stress was started at 0.5 dyn/cm2 
and increased up to 20 dyn/cm2 at 1 min intervals. Cell detachment was calculated by 
normalizing the number of adhered cells relative to the number of cells observed at the 
minimal flow rate of 0.5 dyn/cm2.  
Lymphokine-activated Killer Cell Assay. The LAK cell assay was performed essentially 
as described (Groscurth et al., 1990; Robertson et al., 1990) with 4 x 104 Daudi 
cells/well as targets and 4 x 105 T lymphoblasts as effector cells (Dransfield et al., 
1992a) in triplicates in 96-well U-bottom plates in a final volume of 200 μl. For 
antibody inhibition studies, purified mAbs were used at 50 μg/ml. Then the plates were 
incubated at 37 ºC for 5 h and the percentage of specific target cytolysis is determined 
from the amount of LDH activity, measured as INT reduction, in the culture 
supernatant. 20 μl of lactate solution (Sigma, 36 mg/ml in 10 mM Tris buffer, pH 8.5) 
were added to the cell-free supernatant, followed by addition of 20 μl INT solution 
(Sigma, 2 mg/ml in PBS) and 20 μl of a solution containing NAD+/diaphorase (NAD+: 
Sigma, 3 mg/ml; diaphorase: Boehringer, 13.5 U/ml; BSA: 0.03%; sucrose: 1.2%; in 
PBS) and incubated for 20 min. The reaction was terminated with 20 μl of the LDH 
inhibitor oxamate (Sigma, 16.6 mg/ml in PBS) and the absorbance at 492 nm was 
determined in a microplate reader. 
In situ Proximity Ligation Assays. In situ proximity ligation assays (PLAs) (Duolink kit, 
Olink Bioscience, Uppsala, Sweden) allows detection of direct or closely proximal 
protein–protein interactions in cell samples by fluorescence microscopy (Soderberg et 
al., 2006; Weibrecht et al., 2010). THP-1/PMA cells were seeded, fixed and blocked as 
described above. Next samples were incubated simultaneously with mouse mAbs anti-
β2 TS1/18, anti-αL TS1/11, anti-CD147 VJ1/9 or anti-CD81 5A6 mAbs, and with the 
anti-CD9 H-110 rabbit polyclonal antibody (sc-9148, Santa Cruz Biotechnology), 
followed by specific oligonucleotide-labeled secondary antibodies (anti-mouse-plus 
probe and anti-rabbit minus probe). Only if the two different target proteins are in close 
proximity (≤ 40 nm), the oligonucleotides of the two probes will hybridize and after a 
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rolling-circle amplification reaction and detection with a different fluorescently labeled 
oligonucleotide a fluorescent dot signal can be visualized and analyzed by microscopy. 
Statistical analysis. One-factor ANOVA analysis was performed using the statistics 
software SPSS (IBM). The data distribution was tested for normality by Bonferroni test. 
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3. Results 
3.1. CD9 associates with β2 integrin on the leukocyte surface 
To investigate the possible association between CD9 and the β2 integrin LFA-1, we first 
studied the co-localization of these molecules by double immunofluorescence staining 
with specific mAbs and confocal microscopy analysis. We employed monocytic THP-1 
cells because they constitutively display detectable surface expression of the three major 
β2 integrins (αLβ2, αMβ2 αXβ2) and CD9 (Fig. 1A, upper histograms). Confirming 
previous reports, we observed that the surface expression of both CD9 (Ouchi et al., 
1997; Gutierrez-Lopez et al., 2011) and β2 integrins (Aller et al., 1992) was increased 
during PMA-induced differentiation of THP-1 cells into macrophage-like cells (Fig. 
1A, lower histograms). As shown in Fig. 1B, CD9 and β2 integrin subunit were found 
to co-localize partially on the surface of undifferentiated monocytic THP-1 cells and 
this co-localization became much more evident on PMA-differentiated macrophage-like 
THP-1 (THP-1/PMA) cells, particularly at the cell-cell contact regions in the cellular 
aggregates that form during this differentiation process, as indicated by the increase in 
the Pearson co-localization coefficient. As we reported previously (Rodriguez-
Fernandez et al., 2001), when activation of β2 integrin was induced with extracellular 
divalent cation Mn2+ the localization of β2 integrin molecules changed from an evenly-
distributed pattern to a patched/clustered distribution and interestingly CD9 was clearly 
found co-localizing with clustered β2 integrin. Since the β2-specific mAb stained all the 
β2-containing integrins we also performed double immunofluorescence using an αL-
specific mAb, confirming the pattern of co-localization between CD9 and LFA-1 (Fig. 
1 C). The specificity of the co-localization between CD9 and LFA-1 was evidenced by 
the almost complete lack of co-localization observed between CD9 and CD147 (Supp. 
Fig. 1), which is another abundantly expressed surface protein on these cells (Fig. 1A).   
Similar co-localization results were also observed in other leukocytes, including the B 
lymphoblastic JY and T leukemic Jurkat cells, which only express LFA-1, but not αMβ2 
or αXβ2 (Supp. Fig. 2), and collectively suggest that CD9 associates with β2-integrins, 
and particularly with LFA-1 (αLβ2), on the surface of different types of leukocytic cells. 
To confirm the association of CD9 with LFA-1, co-immunoprecipitation experiments 
were performed using JY and THP-1/PMA cells. All immunoprecipitations were 
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performed using intact cells that were incubated with the immunoprecipitating mAbs at 
37ºC prior to their lysis, thus ensuring that only interactions between cell surface 
molecules were detected. Immunoprecipitation using the β2-specific mAb TS1/18, from 
Brij-97 lysates of THP-1/PMA and JY cells, followed by immunoblotting with anti-
CD9 mAb VJ1/20 clearly showed that this tetraspanin was co-precipitated with integrin 
LFA-1 (Fig. 2A). Co-immunoprecipitation was also detected in the reverse order, i.e. 
immunoprecipitating CD9 followed by immunodetection of β2 integrin (Figure 2B). 
Moreover, the association of LFA-1 with CD9 observed in Brij97-based lysates of THP-
1/PMA and JY cells persisted under more stringent solubilisation conditions such as the 
use of detergent Triton-X100 (1.0 %) (Fig. 3A), thus pointing to a strong/direct type of 
interaction taking place between these molecules on the leukocyte surface. Similar 
results were also obtained using Triton-X100 (1.0 %) lysates of Jurkat cells (not 
shown). Parallel immunoprecipitations were also carried out with cells incubated with 
immunoprecipitating antibodies at 4ºC and subsequently lysed in Triton-X100, to rule 
out that the observed association between CD9 and β2 integrin is caused by pre-
incubation with antibodies at 37ºC (Supp. Fig. 3), and also with cells lysed at 4ºC with 
this detergent prior to the addition of precipitating antibodies, yielding essentially the 
same results (data not shown). 
When chemical crosslinking of solubilized proteins from JY cells was performed with 
thiol-cleavable DTSSP an important increase in the amount of CD9 co-
immunoprecipitated with β2 integrin could be detected after cleavage of the cross-
linked protein complexes in reducing conditions (Figure 3B, left panel). Essentially the 
same results were also obtained with THP-1/PMA cells (data not shown). Furthermore, 
immunoprecipitation with anti-β2 and anti-CD9 mAbs of non-cleaved cross-linked 
protein complexes resolved under non-reducing conditions clearly showed high 
molecular weight complexes of around 300 kDa which were immunodetected both with 
anti-β2 and anti-CD9 antibodies (Figure 3B, right panel), indicating that these 
molecules had been directly cross-linked. It is worth indicating that these ~300 kDa 
bands are compatible with covalently cross-linked complexes containing both LFA-1 
subunits (αL = 185 kDa; β2 = 95 kDa) plus a molecule of CD9 (24 kDa). Definitive 
proof that these ~300 kDa bands correspond to complexes including CD9 and β2 
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integrin, was provided by the fact that they were immunoprecipitated both with anti-β2 
and anti-CD9 antibodies, and immunodetected in both cases with an anti-β2 antibody 
(MEM-48) (Supp. Fig. 4). Taken together, these crosslinking experiments support a 
direct-type of interactions occurring between endogenous LFA-1 and CD9 in leukocytic 
cells. 
Further support for the direct nature of CD9-LFA-1 interaction on the leukocyte surface 
was provided by In situ Proximity Ligation Assays (PLAs) on non-permeabilized 
THP1/PMA cells. PLA signal is only detected when the secondary probes directed 
against the two different molecules whose interaction is suspected are within a short 
range distance (?40 nm) compatible with direct or closely proximal molecular 
interactions. As shown in Fig. 3C, PLA signal between CD9 and both subunits of LFA-
1 (αL and β2) was clearly revealed on the surface of THP-1/PMA cells, being the PLA 
signal particularly evident at cell-cell contact regions. The same procedure with the 
abundantly expressed membrane molecule CD147/EMMPRIN (Fig 1A) did not provide 
any detectable PLA signal, revealing the specificity of PLA signal. As a positive control 
for primary/direct interactions, we assayed the association of CD9 with CD81, as these 
two tetraspanins are known to interact forming heterodimers and higher order oligomers 
on the cell surface (Kovalenko et al., 2004; Le Naour et al., 2006; Gutierrez-Lopez et 
al., 2011). 
Most reported lateral interactions of tetraspanins with other proteins, and particularly 
with integrins, occur through the variable region of their Large Extracellular Loop 
(LEL) domain (Hemler, 2003; Stipp et al., 2003; Levy and Shoham, 2005). To assess 
whether CD9-LFA-1 interaction is mediated through this domain, we carried out pull-
down assays employing a GST-fusion protein corresponding to the LEL domain of CD9 
(CD9-LEL-GST) (Ho et al., 2006; Gilsanz et al., 2013). The β2 subunit of endogenous 
LFA-1 was pulled down by CD9-LEL-GST from Brij-97 (not shown) and Triton-X100 
(Fig. 3D, left panel) lysates of JY cells (and THP-1/PMA cells, not shown). As a 
positive control, another GST construct corresponding to the LEL domain of CD81, a 
tetraspanin closely related to CD9, also pulled-down the β2 integrin subunit, as 
previously reported (Takeda et al., 2003). In contrast, the GST-LEL construct of another 
tetraspanin, CD63, (CD63-LEL-GST) did not pull-down the β2 integrin subunit, 
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reflecting the specificity of these LFA-1/tetraspanin interactions. Furthermore, the CD9-
GST-LEL fusion protein selectively recovered both the β2 and the αL subunits of LFA-
1 from a lysate of biotin-labelled JY cells, indicating that on these cells LFA-1 is a 
major surface protein that is selectively engaged in specific interactions with the LEL 
domain of CD9 (Fig. 3D, right panel). 
 
3.2. CD9 regulates the adhesive function of integrin LFA-1 
We decided to explore whether CD9 could regulate the adhesive function of LFA-1. For 
this goal, we first assessed the effects of several CD9-specific mAbs (VJ1/20, PAINS-
10 and PAINS-13), which exert an agonist-like action on CD9 (Gutierrez-Lopez et al., 
2003; Ovalle et al., 2007; Gutierrez-Lopez et al., 2011; Gilsanz et al., 2013), on LFA-1-
mediated leukocyte adhesion. Treatment of THP-1/PMA cells with the three different 
anti-CD9 mAbs inhibited significantly their adhesion to immobilized ligand ICAM-1 
(Fig. 4A, left panel). The LFA-1-dependence of this assay was confirmed by the nearly 
complete inhibition of adhesion with the blocking anti-β2 mAb Lia3/2 and by the 
important stimulation of adhesion with the β2-activating mAb Kim185. Similar results 
were also obtained with B lymphoblastic JY cells, which do not express β1 integrin 
(Fig. 4B). 
In contrast to freshly isolated resting human lymphocytes, which express very little CD9 
on their surface (Tohami et al., 2004; Barrena et al., 2005), PHA/IL-2-activated 
lymphocytes (“lymphoblasts”) express abundantly the integrin LFA-1 as well as 
variable (from donor to donor) though consistently detectable levels of CD9 on their 
surface, together with modest αMβ2 and negligible αXβ2 integrin expression (Fig. 4C). 
Using these primary human lymphoblasts in static adhesion assays on ligand ICAM-1, 
we observed essentially the same regulatory effects of CD9-specific mAbs on the 
adhesive activity of LFA-1 (Fig. 4D), indicating that CD9 exerts inhibitory effects on 
LFA-1-mediated adhesion. 
Interaction of integrin LFA-1 with specific ligands is a crucial step in many leukocyte 
intercellular interactions and particularly in the cytotoxic lymphocyte-mediated killing 
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of target cells (Blanchard et al., 1987; de Vries et al., 1989; Dransfield et al., 1992a; 
Hogg et al., 2003; Anikeeva et al., 2005). Interestingly, the observed inhibitory effect 
exerted by anti-CD9 mAbs (VJ1/20, PAINS-10 and PAINS-13) on LFA-1 was also 
reflected in LAK (lymphokine-activated killer cells)-mediated killing of target Daudi 
cells (Fig. 4E). The allosterically inhibiting anti-CD18 mAb TS1/18 (Salas et al., 2004) 
was used as a blocking control. Taken together, these results confirm that mAbs with 
agonist-like effect on CD9 regulate negatively the adhesive function of LFA-1. 
We next wanted to address whether changes in the expression levels of CD9 could also 
regulate LFA-1 adhesiveness, either by ectopically expressing this tetraspanin in the 
CD9-deficient HSB-2 T lymphoblastic cell line or, conversely, by suppressing CD9 
expression using shRNA interference in Jurkat T cells (Fig. 5A and B). Ectopic 
expression of CD9 in HSB-2 cells reduced significantly LFA-1-mediated adhesion to 
immobilized ligand ICAM-1 (Fig. 5C), whereas silencing CD9 in Jurkat cells enhanced 
LFA-1-mediated adhesion to ICAM-1 (Fig. 5D). Interestingly, incubation of HSB-
2/CD9 and Jurkat T cells with the anti-CD9 mAbs VJ1/20, PAINS-10 and PAINS-13, 
further reduced LFA-1-mediated adhesion to ICAM-1, confirming the agonist-like 
effect of these mAbs on CD9 function.  
3.3. CD9-mediated regulation of LFA-1 adhesion does not involve changes in integrin 
affinity but alters its clustering  
Integrin adhesive capacity is mainly regulated by two different mechanisms involving 
either, alterations in the conformation of individual integrin molecules that are reflected 
by affinity changes, or modifications in the aggregation of integrin molecules which 
affect the valency of their interactions with ligand. To investigate which of these 
mechanisms is involved in the observed CD9-mediated inhibition of LFA-1 adhesive 
function, we first analysed the induction of expression of the m24 epitope by divalent 
cation Mn2+, which reports the high affinity conformation of LFA-1. As shown in Fig. 
6A, expression of m24 epitope was similarly induced by Mn2+ (over the 10-400 μM 
concentration range) on cells expressing CD9 (HSB-2/CD9 and JK TR2 cells) and on 
their respective counterparts lacking CD9 (HSB-2 and JK shCD9), clearly indicating 
that the presence of this tetraspanin does not interfere with the affinity state of LFA-1. 
As expected, Mn2+ induced LFA-1-mediated adhesion of JK (Fig. 6B) and HSB-2 (Fig. 
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6C) T cells in a concentration-dependent manner over a 20-400 μM range. Interestingly, 
the differences in static cell adhesion between cells lacking CD9 and their CD9-
expressing counterparts disappeared at the highest (400 μM) Mn2+ concentration. The 
inhibitory effect of anti-CD9 mAb VJ1/20 was also abrogated at 400 μM Mn2+. These 
results show that CD9 does not affect LFA-1 adhesive function when cell adhesion is 
mediated by integrin molecules in the high affinity state (i.e. at high Mn2+ 
concentration). 
However, when T cell adhesion was promoted with phorbol ester PMA (at 50 and 200 
ng/ml), which induces the intermediate affinity state of LFA-1 as well as ligand-
dependent clustering of this integrin, CD9-caused inhibition of static adhesion was 
clearly observed even at the highest PMA dose (200 ng/ml) (Fig. 7A and B), suggesting 
that CD9 effect was somehow related to the aggregation/clustering of LFA-1. It is worth 
indicating that these CD9-caused inhibitory effects on adhesion are still maintained at 
higher concentrations of PMA (400 ng/ml) (data not shown), although cell viability 
under these conditions begins to be compromised. Importantly, these differences in 
PMA-induced LFA-mediated cell adhesion to ICAM-1 between T cells expressing or 
lacking CD9 were also consistently observed under flow conditions, therefore 
highlighting the relevance of CD9-mediated regulation of LFA-1 function under 
conditions that resemble a more physiological setting (Fig. 7C). 
To analyse in more detail the implication of CD9 in the organization of LFA-1 
molecules, we first quantitated the number and size of LFA-1 clusters on the adhesive 
surface of PMA-stimulated T cells either expressing (JK TR2) or lacking CD9 (JK 
shCD9). As shown in Fig. 8A (upper panel), the number of PMA-induced LFA-1 
clusters detected by confocal miscroscopy on the cellular adhesive surface in contact 
with immobilized ligand ICAM-1 was significantly higher on Jurkat T cells expressing 
CD9 than on their CD9-silenced counterparts. Interestingly, although fewer LFA-1 
clusters were observed on cells lacking CD9 expression, their size was bigger than on 
CD9-expressing cells. Likewise, the presence of CD9 induced the organization of LFA-
1 molecules into an increased number of smaller clusters in PMA-stimulated monocytic 
U937 cells adhering onto ICAM-1 (Fig. 8A, lower panel). These results were 
corroborated by TIRF microscopy, which recognizes with high resolution and high 
signal-to-noise ratio the organization of cell surface molecules located specifically in 
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the area of contact with the substrate (ICAM-1). Quantitation of fluorescence from 
TIRF microscopy images shows that CD9-expressing T cells (JK TR2) display an 
increased number of clusters but of a smaller size as well as a significant proportion of 
LFA-1 molecules with a dispersed/unclustered appearance, compared to their CD9-
lacking (JK shCD9) cell counterparts (Fig. 8B).  
As a complementary biochemical approach to get further insight on how CD9 affects 
the organization of LFA-1 molecules on the leukocyte surface, the differential resistance 
of LFA-1 molecules to extraction with increasing concentrations of detergent Triton X-
100 (ranging from 0.02 to 1%) in Jurkat  cells expressing (JK TR2) or lacking CD9 (JK 
shCD9) was analysed. As shown in Fig. 8C, LFA-1 molecules were much more easily 
extracted when CD9 is expressed on the cell surface, as would be expected from the 
increased proportion of LFA-1 found in a dispersed/unclustered form and organized in 
smaller clusters. 
Collectively, the confocal and TIRF microscopy data together with the biochemical 
extraction results show that CD9 affects the organization of LFA-1 molecules into 
clusters, as evidenced by the differences in the number and size of LFA-1 aggregates on 
the cell surface as well as by their resistance to detergent extraction. 
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4. Discussion 
We report here that the β2 integrin LFA-1 associates with CD9 in different types of 
leukocytes, including T (Jurkat) and B (JY) lymphocytic cell lines, and PMA-
differentiated THP-1 macrophage-like cells.  
The CD9/LFA-1 association was evidenced by co-localization, in situ Proximity 
Ligation Assays (PLA), as well as biochemical studies based on co-
immunoprecipitation, chemical cross-linking and pull-down assays.  These interactions 
resist stringent cell solubilization conditions (i.e. 1% Triton X-100) in co-
immunoprecipitation and pull-down experiments which, together with chemical cross-
linking and PLA data, collectively support the direct nature of the interaction between 
CD9 and LFA-1. Both co-localization and PLA signal were particularly evident at the 
cell-cell contact regions of THP-1 cell aggregates formed during their PMA-induced 
differentiation process, which are areas enriched in LFA-1 molecules actively engaged 
in interactions with ICAM-1 ligand expressed on opposing cells, suggesting that the 
association of CD9 with LFA-1 might be important in the regulation of LFA-1 adhesive 
function. Tetraspanin-integrin interactions seem to be consistently mediated through the 
variable region of the LEL domain of tetraspanins (Yauch and Hemler, 2000; 
Berditchevski et al., 2001; Hemler, 2005; Charrin et al., 2009); in this regard our pull-
down experiments with a recombinant construct corresponding to the CD9 LEL-domain 
indicate that the interaction between β2 integrin and CD9 is also mediated by this 
domain. 
After demonstrating the existence of CD9-LFA-1 complexes in different types of 
leukocytes we next explored whether CD9 exerted any functional effects on the 
adhesive capacity of LFA-1. For this purpose, we have made use of three different anti-
CD9 mAbs (VJ1/20, PAINS-10 and PAINS-13) considered to exert, at the cellular 
level, an agonist-like action on the basis that in different cellular systems the functional 
effects caused by treating CD9+ cells with these antibodies are similar to those derived 
from the neo- or over-expression of CD9, but opposite to those observed after silencing 
this tetraspanin (Ovalle et al., 2007; Gutierrez-Lopez et al., 2011; Gilsanz et al., 2013). 
The use of these three anti-CD9 mAbs, as well as ectopic expression of CD9 in HSB-2 
T cells or silencing the endogenous CD9 expression in Jurkat T cells using specific 
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shRNAs, collectively show that CD9 exerts a negative regulatory role on LFA-1-
mediated leukocyte adhesion. Consistently with the CD9 inhibitory effect on adhesion, 
LAK-cellular cytotoxicity against target cells, which is largely dependent on LFA-1-
mediated intercellular adhesion, was also inhibited by these anti-CD9 mAbs. 
Engagement of tetraspanins CD81 or CD82 with specific mAbs or overexpression of 
these molecules on T cells have been reported to up-regulate the adhesive and signalling 
capacities of the integrin LFA-1 (Shibagaki et al., 1999; VanCompernolle et al., 2001), 
whereas for the tetraspanin CD9 we report here the opposite: a clear inhibitory effect on 
LFA-1-mediated cellular adhesion and in vitro cellular cytotoxicity. One possibility is 
that the different functional effects of distinct tetraspanins on LFA-1 adhesive function 
might depend on the specific cellular system under study or the specific ligand 
employed (ICAM-3 employed in some of these previous reports versus ICAM-1 
employed here), or alternatively CD9 may exert specific functional effects on LFA-1. 
Integrin adhesive capacity can be regulated essentially by mechanisms involving either 
alterations in the affinity of individual integrin molecules or changes in their 
aggregation/clustering on the cell surface which regulate the valency of their 
interactions with ligand. As reported by the expression of the m24 epitope, the high 
affinity conformation of LFA-1 induced by Mn2+ was not altered by ectopic expression 
or silencing of CD9; accordingly, no differences were observed in LFA-1-mediated 
adhesion stimulated by 400 μM Mn2+ between cells expressing or lacking CD9. In 
contrast, it is interesting that at lower Mn2+ concentrations (20 and 40 μM), at which 
presumably only a proportion of total LFA-1 molecules are in the high affinity 
conformation, differences in adhesion between cells expressing or lacking CD9 could be 
observed. Moreover, the differences between cells expressing and lacking CD9 were 
also consistently observed when cell adhesion was promoted with PMA, which induces 
the intermediate affinity state of LFA-1 as well as ligand-dependent clustering of this 
integrin. All these results clearly indicated that the effect of CD9 on LFA-1-mediated 
adhesion was mainly related to the aggregation/clustering state of this integrin and not 
to changes in its affinity. Indeed, confocal and TIRF microscopy analyses of PMA-
induced LFA-1 clustering specifically at the adhesive cellular surface in contact with 
immobilized ligand ICAM-1 showed that in leukocytic cells expressing CD9 an 
increased number of clusters but with a smaller size could be detected in comparison 
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with their CD9-lacking cell counterparts. TIRF microscopy images also revealed that in 
T cells expressing CD9 a significant proportion of LFA-1 molecules showed a 
dispersed/unclustered appearance, which might correspond to the nanoclusters of LFA-
1 that have been characterized by other higher resolution microscopy techniques. In this 
regard, through the use of NSOM (near-field scanning optical microscopy) and SDT 
(single dye tracking) super-resolution optical techniques, it has been recently reported 
that LFA-1 is preorganized in nanoclusters in “hotspot” regions of the leukocyte 
membrane. Ligand binding favors the lateral mobility and growth of LFA-1 clusters 
through coalescence of individual nanoclusters to form microclusters, in a process that 
also critically depends on transient cytoskeleton anchorage, which in turn mediate 
efficient stable leukocyte adhesion under shear flow (van Zanten et al., 2009; Bakker et 
al., 2012). Our findings are therefore compatible with these observations, and we can 
speculate that CD9 might have an important role in regulating these transitions among 
the different states of LFA-1 organization into distinct types of differently-sized clusters 
as well as the anchorage to the actin cytoskeleton. 
Interestingly, we have observed that the β1 integrin-mediated adhesion of leukocytes to 
the extracellular matrix protein fibronectin was enhanced by anti-CD9 mAbs or 
following ectopic expression of this tetraspanin (data not shown), which concurs with 
our previous data with colorectal carcinoma cells (Ovalle et al., 2007). Therefore, CD9 
seems to have a dual functional regulatory role on leukocyte adhesion mechanisms by 
increasing β1 adhesion to fibronectin but down-regulating LFA-1-mediated adhesion. 
Reciprocal control of the activity of members of distinct subfamilies of integrins co-
expressed on the same cell has been previously described. For instance, in some 
leukemic T cell lines functionally active integrin α4β1 occurs only when LFA-1 is 
either not expressed or inactive (van Kooyk et al., 1993), whereas in human 
erythroleukemic K562 cells transfected with integrin αvβ3, ligation of the β3 integrin 
subunit inhibits the phagocytic function of endogenously expressed α5β1 integrin 
(Blystone et al., 1994; Blystone et al., 1995). Similarly, in human T lymphoblasts 
induction of activation of LFA-1 resulted in decreased adhesion through α4β1 and α5β1 
integrins, rendering cells with a less adhesive and more migratory phenotype (Porter 
and Hogg, 1997). However, the underlying mechanisms for this type of regulation are 
still unclear. Association with cytoskeleton is essential for integrin activation and 
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adhesion. Interestingly, actin cytoskeleton seems to play a differential role in the control 
of β1 and β2 integrin function. In this regard, in resting leukocytes LFA-1 molecules are 
maintained in an inactive low-avidity state through association with actin 
microfilaments and release from these cytoskeletal constraints, caused by drugs such as 
cytochalasin D or latrunculin B, increases their lateral diffusion which is accompanied 
by enhanced clustering and avidity and augmented LFA-1-mediated leukocyte adhesion 
to ICAM-expressing cells (Kucik et al., 1996; van Kooyk and Figdor, 2000). In 
contrast, most β1 integrins (with the notable exception of α4β1 interaction with VCAM-
1) mediate a more stable type of cell adhesion to extracellular matrix proteins such as 
fibronectin, collagen and laminin, and for this purpose seem to require firmer links with 
cytoskeletal components (Sanchez-Mateos et al., 1996; Berrier and Yamada, 2007; 
Chen et al., 2013). Several tetraspanins, including CD81 and CD9, are linked to actin 
microfilaments through ERM (Ezrin-Radixin-Moesin) proteins, either directly or 
through tetraspanin-associated partners EWI-2 and EWI-F (Sala-Valdes et al., 2006). 
The fact that CD9 may modulate in an opposite manner the adhesive function of β2 and 
β1 integrins points to CD9-centered TEMs as crucial players in this balanced regulation. 
An attractive possibility is that, by reinforcing the integrin-cytoskeletal links, CD9 may 
restrict the membrane lateral diffusion of LFA-1 molecules resulting in inhibition of its 
adhesive function, while at the same time, stabilizing β1 integrins with concomitant 
adhesion enhancement to matrix components. Further research will be required to 
properly address this attractive hypothesis. 
The model depicted in Figure 9 summarizes the main findings of this report. State “1” 
in the model is characterized by expression of dispersed and inactive/bent form of LFA-
1 (Low-valency/Low-affinity) and by the absence/very low expression of CD9, as 
occurs physiologically in most resting/non-stimulated lymphocytes (Tohami et al., 
2004; Barrena et al., 2005). Conversion from state “1” into a High-
valency/Intermediate-affinity state (“2”) is characterized by aggregation of integrin 
molecules into large clusters and the acquisition of intermediate affinity conformation, 
both induced by phorbol ester PMA. Within the context of TEMs, augmented CD9 
function induced by its ectopic neoexpression (or by the use of agonist-like mAbs to 
this tetraspanin, not shown in the model), alters the organization of LFA-1 molecules at 
the cell adhesion surface, as evidenced by an increase in “dispersed” LFA-1 molecules 
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and in the number of clusters with a reduced size, defining an Intermediate-
valency/Intermediate-affinity state (“3”) characterized by diminished adhesive 
efficiency to ligand ICAM-1 relative to state “2”. On the other hand, state “4” is 
induced by high concentration of Mn2+ and is characterized by clustering of LFA-1 
molecules in a high affinity conformation (High-valency/High-affinity state); in this 
case, transition from state “4” into “5”, caused by the ectopic expression of CD9 (or by 
the use of agonist-like mAbs to this tetraspanin, not shown in the model), is not 
accompanied by a down-modulation of the adhesive efficiency because, although 
probably some reduction in the ligand-interaction valency occurs, this effect is not 
potent enough to decrease cell adhesion when mediated by a majority of LFA-1 
molecules in the high affinity conformation. The inhibitory effects on LFA-1-mediated 
cell adhesion (observed in transitions “2”→”3”) could place CD9 as a novel target for 
therapeutic intervention aimed at reducing the activity of LFA-1, which would be 
potentially beneficial in a number of inflammatory disorders. 
 
5. Conclusions 
Our data demonstrate that the tetraspanin CD9 associates with integrin LFA-1 in 
different types of leukocytes, and through these interactions, CD9 exerts inhibitory 
effects on LFA-1 adhesive function and leukocyte cytotoxic activity. The mechanism 
responsible for this negative modulation exerted by CD9 does not involve changes in 
the affinity state of LFA-1 but relates to alterations in its state of aggregation. These 
data contribute to our understanding of the regulation of adhesive activity of LFA-1, an 
integrin that plays a pivotal role in many crucial leukocyte functions that require 
intercellular adhesion. 
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Figure Legends: 
 
FIGURE 1. CD9 co-localizes with LFA-1 on THP-1 cell surface. A) Flow cytometric detection 
of CD9 (mAb VJ1/20), β2 (mAb TS1/18), αL (mAb TP1/40), αM (mAb Bear-1), αX (mAb HC1/1) 
and CD147 (mAb VJ1/9) proteins on the surface of THP-1 monocytic cells or THP-1/PMA 
macrophage-like cells. Gray filled histograms correspond to negative controls; empty histograms 
correspond to the expression of the indicated molecules. The numbers in boxes represent M.F.I. 
values. B) and C) Confocal microscopy of THP-1, THP-1 in the presence of 0.4 mM Mn2+ and 
THP-1/PMA differentiated cells showing in panel B co-localization of CD9 (green) and β2 (red) 
and in panel C co-localization of CD9 (green) and αL (red) at the cell surface. Representative 
images of confocal sections for each channel (green and red) and merged channels are shown 
together with co-localization histograms (right panels) showing Pearson co-localization values. 
Scale bars = 5 μm. 
 
FIGURE 2. Co-immunoprecipitation analysis of the association between LFA-1 and CD9.  
THP-1/PMA (left panels) and JY (right panels) cells were incubated with the immunoprecipitating 
mAbs TS1/18 (anti-β2) in panel A, and VJ1/20 (anti-CD9) in panel B, prior to their lysis in 1% Brij-
97-containing lysis buffer. Protein immunocomplexes were precipitated with Protein-G-sepharose, 
then resolved by 8% (for detection of β2) or 12% (for detection of CD9) SDS-PAGE under non-
reducing conditions, and immunoblotted with anti-β2 (MEM-48) (upper panels) or anti-CD9 
(VJ1/20) (middle panels) biotin-conjugated mAbs or with anti-CD105 or anti-CD59 control 
proteins (lower panels). Blots are representative of three different experiments. In some cell 
lysates, several β2 bands (indicated by grey arrowheads), probably corresponding to differences 
in glycosylation or partial degradation, are immunodetected. WL: whole cell lysate. pG: Protein-G-
sepharose without precipitating antibody.  
 
FIGURE 3. Direct interaction of CD9 and LFA-1 at the cell surface is mediated by the Large 
Extracelular Loop of CD9. A) THP-1/PMA or JY cells were lysed with 1% Triton-X100-based 
lysis buffer after incubation with immunoprecipitating mAbs TS1/18 (anti-β2) or VJ1/20 (anti-
CD9). Immunoblotting of co-immunopreciptated proteins was performed as described in Materials 
and Methods. WL: whole cell lysate. pG: Protein-G-sepharose without precipitating antibody. B) 
1% Brij-97 extracts of JY cells were treated with DTSSP cross-linker and Triton X-100 was then 
added to a final concentration of 1% (v/v) to cross-linked lysates and to parallel non-cross-linked 
lysates used as controls, as indicated. Samples were immunoprecipitated with anti-β2 integrin 
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mAb TS1/18 (as indicated in the left panel and lanes 1 and 2 in the right panel) or with anti-CD9 
mAb VJ1/20 (lanes 3 and 4 in the right panel), resolved by SDS-PAGE either under reducing 
conditions to break the thiol bond in DTSSP-crosslinked protein complexes (left panel) or under 
non-reducing conditions (right panel) and subsequently immunodetected with biotinylated anti-
CD9 (VJ1/20) or anti-β2 integrin (MEM-48) mAbs. C) In situ proximity ligation assays (PLAs) were 
performed on THP-1/PMA macrophage-like cells as described in Materials and Methods. Red 
fluorescent dots reveal molecular interactions between CD9 and β2 or αL integrin subunits of 
LFA-1. The interactions between CD147/CD9 and CD81/CD9 are also shown as negative and 
positive controls, respectively (left panels). Maximal projections of representative confocal stacks 
are shown. Scale bars = 5 μm. The right panel shows the quantitation of total fluorescence per 
cell.  ***p < 0.001. D) Non biotinylated (left panel) or surface-biotinylated (right panel) JY cells 
were lysed in Triton-X100-based buffer and incubated with the LEL-GST constructs of human 
CD81 or CD9, as indicated. The GST and CD63-LEL-GST constructs were used as negative 
controls for specificity of binding. Formed complexes were pulled-down with glutathione-
sepharose beads. For non-biotinylated cells, the presence of β2 integrin in the pulled-down 
complexes was revealed by immunoblotting with mAb MEM-48 (upper left-panel) and loading 
controls of GST fusion proteins stained with anti-GST polyclonal antibody are also shown (lower 
left-panel). For surface-biotinylated cells, all lysate proteins pulled-down by GST, CD63-LEL-GST 
or by CD9-LEL-GST were isolated with glutathione-sepharose beads and detected with 
streptavidin-HRP. As a control, β2 integrin was also immunoprecipitated with mAb TS1/18 from 
1% Triton-X100 lysates of either surface-biotinylated or non biotinylated (NB) JY cells and 
detected with streptavidin-HRP (which also clearly reveals the accompanying biotinylated 185 
kDa band corresponding to the αL subunit of LFA-1) or by immunodetection with anti-β2 mAb 
MEM48, respectively.  
 
FIGURE 4. Anti-CD9 mAbs inhibit LFA-1 adhesion and LAK citotoxicity. A) THP-1/PMA cells 
were loaded with the fluorescent probe BCECF-AM (Sigma) and then allowed to adhere to ICAM-
1-Fc-coated wells (6 μg/ml) for 20 min at 37 ºC in the presence of the indicated mAbs (20 μg/ml). 
Data represent the percentage of adherent cells (mean ± SEM of four experiments, each 
performed in triplicates) that remains in the wells after washing non-adherent cells. B) JY B 
lymphocytic cells, loaded with the fluorescent BCECF-AM probe, were seeded in 96-well plates 
pre-coated with ICAM-1-Fc (12 μg/ml) and incubated for 20 min a 37 ºC with the corresponding 
mAbs (20 μg/ml) specified. The bars-graph represents the percentage of adhesion (mean ± 
SEM) of 3 different experiments, performed in triplicates. C) Flow cytometric analysis of CD9 
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(mAb VJ1/20), β2 (mAb TS1/18), αL (mAb TP1/40), αM (mAb Bear-1) and αX (mAb HC1/1) 
surface molecules on human T-lymphoblasts from two different donors. D) Adhesion of T-
lymphoblasts to plastic-immobilized ICAM-1-Fc (6 μg/ml). Cells were allowed to adhere for 20 
min in the presence of the specified mAbs (20 μg/ml). Data shown correspond to the percentages 
of adherent cells (mean ± SEM of four experiments) relative to 100% cell adhesion (dotted line) 
considered in the absence of antibody treatment. E) LAK cytotoxic cells were pre-treated with 
control anti-HSPA8 mAb (PAINS-18), anti-CD9 antibodies (VJ1/20, PAINS-10 and PAINS-13) or 
the inhibitory anti-β2 antibody TS1/18 and their cytotoxicity was were analysed by incubating 
them with Daudi target cells at a 10:1 (effector:target) ratio. Cytotoxicity was determined from the 
amount of LDH released to the medium. The data show the percentage of cytotoxicity (mean ± 
SEM) of three different experiments performed in triplicates. *p < 0.05, **p < 0.01 and ***p < 
0.001. 
 
FIGURE 5. Ectopic expression or silencing of CD9 regulates LFA-1 mediated adhesion. A) 
and B) Ectopic neoexpression of CD9 in HSB-2 cells was achieved by stable transfection with the 
pcDNA3-CD9 (HSB-2/CD9) plasmid and CD9 knock-down in Jurkat cells was achieved by 
retroviral transduction with CD9-specific shRNA (JK shCD9). Jurkat cells transduced with an 
empty shRNA vector (JK TR2) were used as control. The neoexpression or silencing of CD9 in 
these cells was confirmed by flow cytometric analysis (A) and Western Blotting (B). C) After 
loading cells with BCECF-AM, HSB-2 (left panel) or Jurkat (right panel) cells were allowed to 
adhere for 60 min to immobilized ICAM-1-Fc (12 μg/ml), in the presence or absence of the 
indicated mAbs (20 μg/ml). The graphic shows the percentage of cell adhesion (mean ± SEM) of 
three independent experiments, each performed in triplicates. *p < 0.05 and **p < 0.01. 
 
FIGURE 6. CD9 regulation of LFA-1-mediated adhesion does not involve alteration of 
integrin affinity. A) Flow cytometric analysis of epitope m24 expression induced by Mn2+ (at 10, 
20, 40, 100 and 400 μM) relative to its basal expression in Ca2+/Mg2+ (0.5 mM and 1 mM, 
respectively) on the surface of HSB-2 (dark blue solid line), HSB-2/CD9 (light blue dotted line), JK 
TR2 (red dotted line) and JK shCD9 (brown solid line) cells. B) and C) JK TR2 (red bars) and JK 
shCD9 (brown bars) (B) or HSB-2 (dark blue bars) and HSB-2/CD9 (light blue bars) (C) cells 
were loaded with BCECF-AM. Then cells were treated with different Mn2+ concentrations and 
allowed to adhere for 45 min to immobilized ICAM-1-Fc (12 μg/ml), in the presence or absence of 
the indicated mAbs (20 μg/ml). Each bars panel represents the percentages of adherent cells 
(mean ± SEM of three experiments) for each Mn2+ concentration, and data corresponding to 
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these different Mn2+ concentrations are plotted in the right panel. *p < 0.05, **p < 0.01 and ***p < 
0.001. 
 
FIGURE 7. CD9 regulates PMA-induced LFA-1 adhesion through an increment in integrin 
clustering. A) and B) Prior to adhesion, JK TR2 and JK shCD9 (red and brown bars, 
respectively) (A) or HSB-2 and HSB-2/CD9 (dark and light blue bars, respectively) (B) cells were 
treated 2 hours at 37 ºC with different concentrations of PMA (0, 50 or 200 ng/ml). Then cells 
were loaded with the fluorescent probe BCECF-AM and allowed to adhere to plastic-immobilized 
ICAM-1-Fc (12 μg/ml) for 45 min at 37 ºC in the presence or absence of the indicated mAbs (20 
μg/ml). Data represent the percentages of adherent cells (mean ± SEM of three experiments), 
and data corresponding to these different PMA concentrations are plotted in the right panel. C) 
Adhesion of PMA-stimulated JK TR2 and JK shCD9 cells to ICAM-1 under shear flow conditions. 
Left panel contains a representative image showing the cells that remain adhered for each 
different flow rate, and the right panel graph shows the calculated ratios of adherent cells from 9 
different microscopic fields for each flow rate condition. *p < 0.05, **p < 0.01 and ***p < 0.001. 
Scale bars = 30 μm. 
 
FIGURE 8. CD9 regulates the distribution of LFA-1 molecules into clusters. A) Confocal 
microscopy images of immunofluorescence-stained β2 integrin clustering at the adhesive surface 
in contact with ligand ICAM-1-Fc of PMA-stimulated JK TR2, JK shCD9, U937/pcDNA3 and 
U937/CD9 cells. Representative confocal images are shown on the left panels and quantitation of 
the number and size (mean area) of clusters/cell corresponding to ten individual cells are shown 
on the right panels. *p < 0.05, **p < 0.01 and ***p < 0.001. Scale bars = 5 μm. B) TIRF 
microscopy images of β2 integrin clustering at the adhesive surface in contact with ligand ICAM-
1-Fc of PMA-stimulated JK TR2, JK shCD9. Five representative images are shown for each cell 
type on the left panel and quantitation of the number and size of clusters/cell corresponding to 15 
individual cells are shown on the right panels. ***p < 0.001. Scale bars = 5 μm. C) Differential 
resistance of LFA-1 molecules to extraction with increasing concentrations of detergent Triton X-
100 (0.02 / 0.05 / 0.1 /0.5 %) from PMA-stimulated Jurkat cells either expressing (JK TR2) or 
lacking CD9 (JK shCD9), adhered to ICAM-1-Fc. Extracted LFA-1 was detected by 
immunoblotting with the anti-β2 mAb MEM48, and quantitated relative to β-actin content.  
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FIGURE 9. Hypothetical model which summarizes the regulation by CD9 of the different 
LFA-1 functional states, as described in the Discussion.   
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